期刊文献+

2型糖尿病非酒精性脂肪肝肝损害96例治疗 被引量:1

下载PDF
导出
摘要 临床上对肝功异常的患者使用噻唑烷二酮和调脂药有顾虑,因两种药物均可引起转氨酶升高,本文观察糖尿病合并非酒精性肝损害患者使用胰岛素控制血糖,并应用胰岛素增敏剂吡咯列酮改善胰岛素抵抗(IR)及贝特类调脂的临床效果。1资料与方法1.1资料我院2011年1~12月的475例住院2型糖尿病(T2DM)患者,诊断T2DM合并非酒精性脂肪肝96例为脂肪肝组,年龄(56.61±8.73)岁;其余379例为非脂肪肝组。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2014年第5期1355-1356,共2页 Chinese Journal of Gerontology
基金 辽宁省教育厅课题(No.L2010306)
  • 相关文献

参考文献3

二级参考文献8

  • 1Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1513
  • 2王永高,杨萍.2型糖尿病性肝损害相关因素分析[J].广西医学,2006,28(10):1503-1504. 被引量:9
  • 3Sanyal AJ, Campbell-sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondria abnormalities. Gastroenterology, 2001, 120 : 1183-1197.
  • 4Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Dia betes, 2002, 51: 797-802.
  • 5Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology, 2003, 38: 1008-1017.
  • 6Tiikkainen M, Hakkinen AM, Korsheninnikova E. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tis sue in patients with type 2 diabetes. Diabetes, 2004, 53: 2169-2176.
  • 7Chalasani N, Teal E, Hall SD, et al. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and el- evated baseline liver enzymes. Am J Gastroenterol, 2005, 100: 1317-1321.
  • 8Dailey GE, Noor MA, Park JS, et al. Glycemic control with gly buride/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double blind trial. Am J Med, 2004, 116:223-229.

共引文献10

同被引文献17

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部